Cytimmune and the U.S. Nanotechnology Characterization Laboratory (NCL) have signed a Material Transfer Agreement (MTA). The focus of this agreement is a new nanomedicine construct developed by Cytimmune that simultaneously delivers Interferon gamma (IFN-y) and Tumor Necrosis Factor alpha (TNF alpha) on the same gold nanoparticle. Cytimmune will supply newly formulated therapeutic to the NCL for in vitro studies and characterization. Studies are expected to be initiated in 2021.